Bright Minds Biosciences (DRUG) Competitors $35.99 -0.16 (-0.44%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$36.04 +0.05 (+0.15%) As of 02/21/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends DRUG vs. BCAX, VERV, MNMD, DNTH, AVXL, OPT, SANA, LENZ, QURE, and RLAYShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), Opthea (OPT), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), uniQure (QURE), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Bicara Therapeutics Verve Therapeutics Mind Medicine (MindMed) Dianthus Therapeutics Anavex Life Sciences Opthea Sana Biotechnology LENZ Therapeutics uniQure Relay Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk. Which has higher earnings and valuation, DRUG or BCAX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.17-211.69Bicara TherapeuticsN/AN/AN/AN/AN/A Is DRUG or BCAX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% Bicara Therapeutics N/A N/A N/A Do insiders and institutionals believe in DRUG or BCAX? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor DRUG or BCAX? Bicara Therapeutics received 5 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes6100.00% Underperform VotesNo VotesBicara TherapeuticsOutperform Votes11100.00% Underperform VotesNo Votes Do analysts rate DRUG or BCAX? Bright Minds Biosciences currently has a consensus target price of $84.33, indicating a potential upside of 134.32%. Bicara Therapeutics has a consensus target price of $41.20, indicating a potential upside of 216.92%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor DRUG or BCAX? In the previous week, Bright Minds Biosciences had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 3 mentions for Bicara Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.73 beat Bicara Therapeutics' score of 0.58 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBright Minds Biosciences and Bicara Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.37M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-211.696.1326.4618.82Price / SalesN/A309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book6.146.747.634.64Net Income-$2.06M$138.11M$3.18B$245.69M7 Day Performance-13.90%-2.43%-1.91%-2.66%1 Month Performance7.92%-1.91%-0.19%-2.15%1 Year Performance1,774.58%-5.03%16.70%12.90% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences4.1374 of 5 stars$35.99-0.4%$84.33+134.3%+1,829.8%$253.37MN/A-211.69N/AAnalyst ForecastAnalyst RevisionNews CoverageBCAXBicara TherapeuticsN/A$13.48+2.7%$41.20+205.6%N/A$733.58MN/A0.0032VERVVerve Therapeutics2.922 of 5 stars$8.58+11.3%$25.75+200.1%-44.6%$726.42M$24.40M-3.49110Upcoming EarningsAnalyst ForecastMNMDMind Medicine (MindMed)2.307 of 5 stars$9.89+14.3%$26.33+166.3%+65.2%$725.25MN/A-4.3840Gap UpHigh Trading VolumeDNTHDianthus Therapeutics1.776 of 5 stars$24.49+1.5%$46.83+91.2%-1.3%$724.90M$2.83M-9.8080AVXLAnavex Life Sciences3.7896 of 5 stars$8.52+0.6%$44.00+416.4%+64.4%$722.67MN/A-16.3840Analyst ForecastAnalyst RevisionGap UpOPTOpthea2.0678 of 5 stars$5.21+1.0%$12.00+130.3%+46.8%$710.80M$120,000.000.008Upcoming EarningsGap UpSANASana Biotechnology3.0556 of 5 stars$3.16+12.5%$14.25+350.9%-62.3%$705.53MN/A-2.26380LENZLENZ Therapeutics1.5189 of 5 stars$25.22-0.2%$35.40+40.4%N/A$693.58MN/A0.00110QUREuniQure3.3836 of 5 stars$14.18+7.0%$40.00+182.1%+105.1%$691.13M$15.84M-2.86500Upcoming EarningsRLAYRelay Therapeutics2.2853 of 5 stars$4.00+1.0%$20.50+412.5%-62.6%$669.52M$25.55M-1.53330 Related Companies and Tools Related Companies Bicara Therapeutics Competitors Verve Therapeutics Competitors Mind Medicine (MindMed) Competitors Dianthus Therapeutics Competitors Anavex Life Sciences Competitors Opthea Competitors Sana Biotechnology Competitors LENZ Therapeutics Competitors uniQure Competitors Relay Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRUG) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts